Author:
Yamatodani Takashi,Ekblad Lars,Kjellén Elisabeth,Johnsson Anders,Mineta Hiroyuki,Wennerberg Johan
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference36 articles.
1. Ammarguellat F, Llovera M, Kelly PA, Goffin V (2001) Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun 284:1031–1038. doi: 10.1006/bbrc.2001.5085
2. Barre B, Vigneron A, Perkins N, Roninson IB, Gamelin E, Coqueret O (2007) The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 13:4–11. doi: 10.1016/j.molmed.2006.11.001
3. Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7(suppl 4):2–8. doi: 10.1634/theoncologist.7-suppl_4-2
4. Bianco C, Tortora G, Bianco R et al (2002) Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8:3250–3258
5. Bonner JA, Maihle NJ, Folven BR, Christianson TJ, Spain K (1994) The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 29:243–247
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献